Navigation Links
Long-term Use of Herceptin Does Not Increase Heart Failure in Patients

CHICAGO, A five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago states that the risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time.

The research team developed a prediction model based on these findings. The model will help oncologists to assess the risk of heart failure in individual breast cancer patients before treatment with Herceptin and chemotherapy. These findings, to be announced at the Womens Cancers press briefing at the meeting, will be published in Abstract LBA513 in the ASCO proceedings.

The information we obtained from this study is essential to understanding womens risks for congestive heart failure associated with adding Herceptin to combination chemotherapy for breast cancer treatment, said Priya Rastogi, M.D., study presenter and assistant professor, University of Pittsburgh School of Medicine and assistant director of medical affairs, NSABP. Were encouraged that we found no increase in heart failure risks long-term and now are able to use this knowledge to individualize womens treatment based on their specific cardiac risk factors.

The study assessed cardiac side effects in 1,850 women with HER-2 positive breast cancer those who have abnormally high levels of the HER2/neu protein for five years. Study participants were initially randomized to receive four cycles of a standard combination chemotherapy regimen, doxorubicin and cyclophosphamide followed by paclitaxel, or doxorubicin and cyclophosphamide followed by paclitaxel and Herceptin.

The incidence of congestive heart failure was compared between the two groups. Initial three-year follow-up results reported that although Herceptin provides a clear and notable benefit to women with HER-2 po sitive breast cancer, it also causes an increased risk for congestive heart failure a 4.1 percent incidence of congestive health failure was reported in the Herceptin and chemotherapy group compared to a 0.8 percent increase in the control group.

The current study found that after five years follow-up, the incidence of congestive heart failure was virtually unchanged 3.8 percent of patients who received Herceptin and chemotherapy experienced congestive heart failure, compared to 0.9 percent of patients in the control group. Congestive heart failure was measured using a Multiple Gated Acquisition scan, or a MUGA scan a noninvasive tool that produces a moving image of the beating heart to determine the health of the cardiac ventricles.

The research team also identified possible risk factors for breast cancer patients more likely to develop congestive heart failure from adding Herceptin to combination chemotherapy. They developed a prediction model based on these factors, including hypertension, age and baseline cardiac function.

It is our hope that this model will help to individualize care for women in terms of choice of Herceptin-containing treatment regimens based on their personal risk and benefits, said Dr. Rastogi.


'"/>




Related medicine news :

1. Long-term use of calcium supplements to prevent colon cancer
2. Long-term Care Should Be A Planned Affair
3. Long-term Ibuprofen Therapy After Brain Injury Deteriorate Cognitive Abilities
4. Global AIDS Conference Calls for Long-term Strategies
5. Long-term Use of Stomach Drugs may Weaken Bones
6. Asthma Sufferers Favor Quick Relief Over Long-term Control
7. Long-term Marijuana Smoking Leads to Respiratory Complaints
8. Tamoxifen Yields Long-term Reduction in Breast Cancer Risk
9. Angioplasty Reduces Long-term Cardiac Risk in Heart Patients With silent Ischemia
10. Functional Foods Must Be Monitored to Assess Their Long-term Safety and Effectiveness
11. Cancer Drug Induces HDAC Inhibitor and Enhance Long-term Memory
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with ... Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology: